Amman R, Tissing W, Phillips RS. Rationalising the approach to children with fever in neutropenia. Curr Opinion in Inf Dis. 2012 [In press]
Chambers D, Grant R, Warren E, Pearson S-A, Wilson P. Use of evidence from systematic reviews to inform commissioning decisions: a case study. Evid Policy 2012 [In press]
Golder S, Loke Y. Sensitivity and precision of adverse effects search filters in MEDLINE and EMBASE: a case study of fractures with thiazolidinediones. Health Info Libr J 2012; [Epub ahead of print]
McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S. Dronedarone for the treatment of atrial fibrillation: a NICE Single Technology Appraisal. Pharmacoeconomics 2012;30(1):35-46
Phillips B, Sutton A, Riley R, Chisholm J, Picton S, Stewart L. Predicting infectious complications in neutropenic children and young people with cancer (IPD Protocol). Syst Rev 2012; [In press]
Phillips R, Wade R, Lehrnbecher T, Stewart L, Sutton A. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 2012; 10(1):6. [Epub ahead of print]
Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce I, Sculpher M, Woolacott N. Golimumab for the treatment of psoriatic arthritis: A NICE Single Technology Appraisal. PharmacoEconomics 2012;doi: 10.2165/11595920-000000000-00000. [Epub ahead of print]